Vandetanib

Overview

Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumors of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor, the epidermal growth factor receptor, and the RET-tyrosine kinase. The drug was developed by AstraZeneca who sold the rights to Sanofi in 2015.[1–5] WP

Uses, dosage and effects

Medical use

Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in people with unresectable locally advanced or metastatic disease. Vandetanib is used to treat medullary thyroid cancer in adults who are ineligible for surgery.[3][6][7] WP

Risks and side effects

Contraindications

The V804M mutation in RET confers resistance to Vandetanib anti-RET activity.[7] WP

In people with moderate and severe hepatic impairment, no dosage for vandetanib has been recommended, as its safety and efficacy has not been established yet. Vandetanib is contraindicated in people with congenital long QT syndrome.[2][3][8] WP

Adverse effects

Very common (present in greater than 10% of people) adverse effects include colds, bronchitis, upper respiratory tract infections, urinary tract infections, decreased appetite, low calcium absorption, insomnia, depressed mood, Headache, tingling sensations, weird, painful sensations, dizziness, blurred vision, damage to the cornea, long QT syndrome, high blood pressure, stomach pain, diarrhea, nausea, vomiting, indigestion, sensitivity to sunlight, rash, acne, dry and itchy skin, nail disorders, protein in urine, kidney stones, weakness, fatigue, pain, and edema.[6] WP

Common (present in between 1% and 10% of people) adverse effects include pneumonia, sepsis, influenza, cystitis, sinusitis, laryngitis, folliculitis, boils, fungal infection, kidney infections, low thyroid hormone levels, low potassium, high calcium levels, hyperglycemia, hypercholesterolemia, hypertriglyceridemia, dehydration, low sodium levels, anxiety, tremor, lethargy, loss of consciousness, balance disorders, changes in sense of taste, visual impairment, halo vision, perceived light flashes, glaucoma, pink eye, dry eye, keratopathy, hypertensive crisis, mini strokes, nose bleeds, coughing up blood, defecating blood, colitis, dry mouth, stomatitis, constipation, gastritis, gallstones, Chemotherapy-induced acral erythema, hair loss, painful urination, bloody urine, kidney failure, frequent urination, urgent need to urinate, and fever.[6][9] WP

Interactions

Interactions

Vandetanib has been reported as a substrate for the OATP1B1 and OATP1B3 transporters. Interaction of vandetanib with OATP1B1 and OATP1B3 may alter its hepatic disposition and can lead to transporter mediated drug-drug interactions. Also, vandetanib is an inhibitor of OATP1B3 transporter but not for OATP1B1.[8][10] WP

Other drugs that prolong the QT interval can possibly add to this side effect of vandetanib. As the drug is partly metabolised via the liver enzyme CYP3A4, strong inducers of this enzyme can decrease its blood plasma concentrations. CYP3A4 inhibitors do not significantly increase vandetanib concentrations, presumably because it is also metabolised by flavin containing monooxygenase 1 (FMO1) and 3.[2][3] WP

Pharmacology

Pharmacology

Vandetanib is an inhibitor of vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and RET tyrosine kinases. It weakly inhibits vascular endothelial growth factor receptor-3.[6][11] WP

Vandetanib is well absorbed from the gut, reaches peak blood plasma concentrations 4 to 10 hours after application, and has a half-life of 19 days on average, per pharmacokinetic studies. It has to be taken for about three months to achieve a steady-state concentration. In the blood, it is almost completely (90–96%) bound to plasma proteins such as albumin. It is metabolised to N-desmethylvandetanib via CYP3A4 and to vandetanib-N-oxide via FMO1 and 3. Both of these are active metabolites. Vandetanib is excreted via the faeces (44%) and the urine (25%) in form of the unchanged drug and the metabolites.[2][12][13] WP

Research

Research

AstraZeneca tested Vandetanib in clinical trials for non-small cell lung cancer and submitted an application for approval to the EMA but then withdrew the application in October 2009 after trials showed no benefit when the drug was administered alongside chemotherapy. A clinical trial of vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma was negative in a prospective, randomised, double-blind, multicentre phase 2 trial.[14][15] WP

History

History

Vandetanib was approved by the FDA in April 2011, for treatment of late-stage thyroid cancer.[16] WP

Vandetanib was initially marketed without a brand name; it has been sold under the brand name Caprelsa since August 2011.[17] WP

In 2015, Sanofi acquired the product from AstraZeneca.[18] WP

Chemistry

Formula

C22H24BrFN4O2 PC

CAS number

443913-73-3 PC

Molar mass (g/mol)

475.4 PC

IUPAC name (computed by PubChem)

N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine PC

SMILES

CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC PC

InChIKey

UHTHHESEBZOYNR-UHFFFAOYSA-N PC

PubChem CID

3081361

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Definition of vandetanib. 2 February 2011
2. Other Vandetanib Monograph
3. Journal / agency Caprelsa- vandetanib tablet, film coated. 19 June 2020
4. Other AZ sells rare cancer drug to Sanofi. 27 July 2015
5. Other Genzyme to Buy Caprelsa from AstraZeneca for Up to $300M. 27 July 2015
6. Other UK label. 16 December 2016
7. Journal / agency Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, Lorusso L, Cappagli V, Pieruzzi L, Giani C, Sabini E, Passannati P, Puleo L, Matrone A, Pontillo-Contillo B, Battaglia V, Mazzeo S, Vitti P, Elisei R. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocrine-Related Cancer. April 2016. doi:10.1530/ERC-15-0555 · PMID 27207700
8. Journal / agency Khurana V, Minocha M, Pal D, Mitra AK. Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. Drug Metabolism and Drug Interactions. March 2014. doi:10.1515/dmdi-2013-0062 · PMID 24643910 · PMC4407685
9. Journal / agency Acitelli E, Maiorca C, Grani G, Maranghi M. Metabolic adverse events of multitarget kinase inhibitors: a systematic review. Endocrine. July 2023. doi:10.1007/s12020-023-03362-2 · PMID 37067769 · PMC10239378
10. Journal / agency Khurana V, Minocha M, Pal D, Mitra AK. Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. Drug Metabolism and Drug Interactions. May 2014. doi:10.1515/dmdi-2014-0014 · PMID 24807167 · PMC4407688
11. Journal / agency Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research. December 2002. PMID 12499271
12. Journal / agency Martin P, Oliver S, Kennedy SJ, Partridge E, Hutchison M, Clarke D, Giles P. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clinical Therapeutics. January 2012. doi:10.1016/j.clinthera.2011.11.011 · PMID 22206795
13. Journal / agency Clinical Pharmacology Review: Vandetanib. 20 August 2010
14. Journal / agency Zactima. 17 September 2018
15. Journal / agency Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet. Oncology. April 2017. doi:10.1016/S1470-2045(17)30084-0 · PMID 28259610
16. Journal / agency FDA approves new treatment for rare form of thyroid cancer
17. Other Starkey J. AstraZeneca (finally) lands name for cancer drug. 2 August 2011
18. Other Fourcade M. Sanofi to Buy Caprelsa Drug from AstraZeneca for $300 Million. 27 July 2015

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.